WO2003048779A1 - Verfahren zum nachweis von allergien und verwendung eines antikörpers zum nachweis von allergien - Google Patents
Verfahren zum nachweis von allergien und verwendung eines antikörpers zum nachweis von allergien Download PDFInfo
- Publication number
- WO2003048779A1 WO2003048779A1 PCT/EP2002/013437 EP0213437W WO03048779A1 WO 2003048779 A1 WO2003048779 A1 WO 2003048779A1 EP 0213437 W EP0213437 W EP 0213437W WO 03048779 A1 WO03048779 A1 WO 03048779A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- cells
- basophils
- allergies
- responders
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5403—IL-3
Definitions
- the invention relates to a method for the detection of allergies.
- Allergic reactions can be triggered, for example, by pollen, animal hair and scales, food and pharmaceuticals, dust mites, insect poisons, etc.
- the triggered allergic reactions are expressed e.g. as rhinitis, rash, or even lead to an allergic shock, mostly depending on which body regions the allergens come into contact with.
- Allergic reactions occur when an individual who has already produced IgE antibodies in response to a harmless antigen then comes back into contact with the same allergen. This second exposure initiates a stage of the hypersensitivity reaction.
- the immediate-type allergies are based on hypersensitivity reactions mediated by IgE.
- the IgE formed after contact with an allergen in an excessive reaction bind in particular to mast cells and to basophilic granulocytes (basophils) to their corresponding IgE receptors ("high-affinity receptors", FceRI).
- FceRI basophilic granulocytes
- FceRI basophilic granulocytes
- Hymenoptera allergies i.e. allergies to poisons from cutwings such as bees or wasps
- the diagnosis of Hymenoptera allergies is mainly based on recording the history, skin tests and the determination of specific IgE antibodies.
- the allergen-induced release of histamine or leukotriene C4 is measured in selected cases.
- Other tests are based on flow cytometric analyzes to determine either the binding of fluorescence-labeled allergens to specific, cell-bound IgE molecules or an allergen-induced cell surface expression of basophilic granule antigens.
- hyposensitization involves injecting increasing doses of an allergen to which the patient is sensitive.
- WO 00/72010 describes the use of a monoclonal antibody for the detection of allergies.
- the antibody described in this publication binds to such, increasingly expressed surface structures and thus also serves to quantify activated and non-activated basophils.
- a method for the detection of allergies with this antibody is described.
- non-responders A disadvantage of this method and of the tests mentioned above is that they cannot be used in so-called non-responders. As shown above, histamine is not released and surface structures are not upregulated in non-responders, although the patients concerned may be allergic to a particular allergen. Although non-responders can be positive in skin tests or produce specific IgE antibodies, non-responders cannot be identified as allergy sufferers by a method with which activated and non-activated basophils or the upregulation of certain surface structures are detected.
- the inventors of the present application have recognized that it is possible to treat the surface structure of basophils and / or mast cells and / or progenitor cells of basophils and / after treatment of non-responders, in particular with interleukin IL-3 and subsequent incubation with a specific allergen. or upregulate mast cells to which the anti body 97A6 can bind. Interleukin IL-3 itself induces an upregulation of this surface structure, but the additional upregulation by the allergen is at least a factor of two higher and can therefore be measured.
- Allergy sufferers among the non-responders can use the conventional tests, i.e. Tests in which the status of basophils are determined cannot be recorded, since they do not release histamine after contact with the allergen, nor do they upregulate a certain surface structure to confirm an allergic status.
- the inventors showed that in the case of allergy sufferers among the non-responders, a certain surface structure could be upregulated by the method according to the invention. Through the subsequent incubation with an antibody that recognizes the highly regulated surface structure, the allergy sufferers could be identified among the non-responders and the allergy type clearly assigned.
- the surface structure was not specifically upregulated by an allergen after an incubation with interleukin IL-3, so that these could also be confirmed as actual non-allergy sufferers.
- Interleukins are cytokines that are mainly released by leukocytes after physiological or non-physiological stimuli, and lymphocytes and their progenitor cells from the bone marrow, but also influence other blood cells with regard to their proliferation, differentiation and cell-cell interactions.
- Interleukin IL-3 is mainly formed by antigen-activated T lymphocytes, but also, for example, by endothelial cells, mast cells, monocytes, etc. It has a strong influence on the growth and differentiation of hematopoietic stem cells and promotes the release of histamine and leukotriene C4 from basophilic granulocytes.
- agents which have the effect according to the invention. These include agents that influence cells, for example, through a proliferating and / or stimulating and / or activating effect.
- the inventors were able to show that incubation of blood samples with interleukin IL-3 up-regulated surface structures to which the antibody 97A6 binds.
- the surface structure is phosphodiesterase / nucleotide pyrophosphatase-3 (PDNP3), which is also referred to as E-NPP3 or PD-Ibeta.
- PDNP3 phosphodiesterase / nucleotide pyrophosphatase-3
- E-NPP3 phosphodiesterase / nucleotide pyrophosphatase-3
- PD-Ibeta phosphodiesterase / nucleotide pyrophosphatase-3
- interleukin IL-3 1 to 20 ng / ml, preferably of approximately 10 ng / ml, is used.
- the blood sample is incubated with interleukin IL-3 between one hour and 96 hours, preferably overnight, that is to say for approximately 24 hours.
- the inventors were able to show that the stimulation index was optimal at 24 hours so that the test could also be carried out on responders. It is further preferred if a monoclonal antibody, in particular the antibody 97A6, is used as the antibody, which is produced and released by hybridoma cells, which on February 12, 1997 under the number DSM ACC 2297 at the German Collection of Microorganisms and Cell Cultures GmbH, DSMZ, according to have been deposited with the Budapest Treaty. The retention period has been extended accordingly.
- This antibody has already been tested in clinical practice and is sold by Beckman Coulter under the order number IM3575.
- This antibody specifically recognizes an epitope of the surface structure phosphodiesterase / nucleotide pyrophosphatase-3 (PDNP3), which is allergen-specifically upregulated in allergy sufferers.
- PDNP3 surface structure phosphodiesterase / nucleotide pyrophosphatase-3
- an antibody that binds to a different epitope of PDNP3 than antibody 97A6 it is preferred to use an antibody that binds to a different epitope of PDNP3 than antibody 97A6.
- this can result in an amplification of the detection signal, since more antibodies can then bind to a cell.
- an antibody which is linked to a marker, in particular to a fluorescence marker.
- the antigen can thus be detected with a high level of sensitivity, which is why only small amounts of the antibody then have to be used for the detection.
- Bound antibodies are then detected, for example, by conventional immunological detection methods, for example ELISA (enzyme-linked immunosorbent assay) or by a FACS analysis.
- ELISA enzyme-linked immunosorbent assay
- FACS analysis a FACS analysis of cells.
- the method for the detection of allergies is used in samples that have been identified as non-responders in allergy tests.
- IL-3 is used to carry out the detection of allergies in the samples which had a non-responder status in a first test with the allergen.
- an antibody is attached to those surface structures of basophils and / or mast cells and / or progenitor cells of basophils and / or mast cells binds to which the antibody labeled 97A6 can bind, used to detect allergies from non-responders.
- Blood cells from non-responders (allergy sufferers and normal people) and from responders were stimulated with 10 ng / ml interleukin IL-3 at a temperature of 37 ° C for 3 hours (1 hour, 24 hours, 48 hours, 96 hours) (3 ml peripheral whole blood in 10 ml whole medium plus 10 ng / ml interleukin IL-3).
- the incubation was carried out in 25 cm 2 tissue culture areas at 37 ° C and at 5% CO 2 .
- Expression of E-NPP3 was measured at zero hours (before incubation), one hour, one day, two days, three days (or four days), and six days after interleukin IL-3 incubation.
- the samples were then incubated for 15 minutes at 37 ° with serial dilutions of bee and wasp venom or PBS (phosphate-buffered saline) plus calcium (negative control) or anti-IgE (positive control).
- the reaction was stopped with 20 mmol EDTA solution and the cells were resuspended in 50 ⁇ l FACS buffer (0.1% NaN 3 + 0.1% BSA, in "Hank's balanced salt solution").
- the cells were then incubated with 10 ul 97A6-PE antibody (1 ug / ml final concentration) for 15 min at room temperature.
- erythrocyte lysis reagent analysis, immunotech
- 2 ml of erythrocyte lysis reagent analysis, immunotech
- 2 ml of FACS buffer was added and the sample was centrifuged at 1200 rpm for 7 min. The supernatant was discarded, 4 ml of FACS buffer was added to the pellet and the sample was centrifuged again at 1200 rpm for 7 min. After discarding the supernatant, the pellet containing the cells was taken up in 150 ⁇ l of FACS buffer and kept on ice.
- the cells were then analyzed in flow cytometry (FACScalibur).
- the change in E-NPP3 expression was determined by calculating the stimulation index (SI) and the percentage of basophils stimulated.
- the stimulation index is calculated from: mean fluorescence intensity from allergen or anti-IgE-stimulated 97A6 + cells / mean fluorescence intensity from PBS-stimulated 97A6 + cells.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02785415A EP1454141B1 (de) | 2001-12-06 | 2002-11-28 | Verfahren und verwendung eines antikörpers zum nachweis von allergien |
AU2002350717A AU2002350717A1 (en) | 2001-12-06 | 2002-11-28 | Method for detecting allergies and use of an antibody to detect allergies |
US10/861,892 US20050003461A1 (en) | 2001-12-06 | 2004-06-04 | Method for detecting allergies |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10160921.3 | 2001-12-06 | ||
DE10160921A DE10160921B4 (de) | 2001-12-06 | 2001-12-06 | Verfahren zum Nachweis von Allergien und Verwendung eines Antikörpers zum Nachweis von Allergien |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/861,892 Continuation US20050003461A1 (en) | 2001-12-06 | 2004-06-04 | Method for detecting allergies |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003048779A1 true WO2003048779A1 (de) | 2003-06-12 |
Family
ID=7708864
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2002/013437 WO2003048779A1 (de) | 2001-12-06 | 2002-11-28 | Verfahren zum nachweis von allergien und verwendung eines antikörpers zum nachweis von allergien |
Country Status (6)
Country | Link |
---|---|
US (1) | US20050003461A1 (de) |
EP (1) | EP1454141B1 (de) |
AT (1) | ATE396405T1 (de) |
AU (1) | AU2002350717A1 (de) |
DE (1) | DE10160921B4 (de) |
WO (1) | WO2003048779A1 (de) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1863848A2 (de) * | 2005-03-31 | 2007-12-12 | Agensys, Inc. | An 161p2f10b-proteine bindende antikörper und verwandte moleküle |
US7655234B2 (en) | 2001-11-07 | 2010-02-02 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer |
US7772011B2 (en) | 2005-03-21 | 2010-08-10 | Ronald Joseph Harbeck | Method and kit for detection of autoimmune chronic urticaria |
US8350009B2 (en) | 2005-03-31 | 2013-01-08 | Agensys, Inc. | Antibodies and related molecules that bind to 161P2F10B proteins |
US8609092B2 (en) | 2010-02-08 | 2013-12-17 | Agensys, Inc. | Antibody drug conjugates (ADC) that bind to 161P2F10B proteins |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111610326B (zh) * | 2020-06-02 | 2023-10-13 | 苏州艾乐给予生物科技有限公司 | 一种用于过敏原检测的体外肥大细胞组胺释放的检测方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2008687C1 (ru) * | 1991-12-24 | 1994-02-28 | Елена Семеновна Нишева | Способ диагностики отсроченной аллергической реакции |
WO2000072010A1 (de) * | 1999-05-19 | 2000-11-30 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Verwendung eines antikörpers zur detektion von basophilen und/oder mastzellen |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998032014A1 (de) * | 1997-01-20 | 1998-07-23 | Orpegen Pharma Gmbh | Basophilen-degranulationstest |
-
2001
- 2001-12-06 DE DE10160921A patent/DE10160921B4/de not_active Expired - Fee Related
-
2002
- 2002-11-28 WO PCT/EP2002/013437 patent/WO2003048779A1/de active IP Right Grant
- 2002-11-28 AU AU2002350717A patent/AU2002350717A1/en not_active Abandoned
- 2002-11-28 EP EP02785415A patent/EP1454141B1/de not_active Expired - Lifetime
- 2002-11-28 AT AT02785415T patent/ATE396405T1/de not_active IP Right Cessation
-
2004
- 2004-06-04 US US10/861,892 patent/US20050003461A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2008687C1 (ru) * | 1991-12-24 | 1994-02-28 | Елена Семеновна Нишева | Способ диагностики отсроченной аллергической реакции |
WO2000072010A1 (de) * | 1999-05-19 | 2000-11-30 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Verwendung eines antikörpers zur detektion von basophilen und/oder mastzellen |
Non-Patent Citations (2)
Title |
---|
BUEHRING HANS-JOERG ET AL: "The monoclonal antibody 97A6 defines a novel surface antigen expressed on human basophils and their multipotent and unipotent progenitors.", BLOOD, vol. 94, no. 7, 1 October 1999 (1999-10-01), pages 2343 - 2356, XP002234798, ISSN: 0006-4971 * |
YAMAGUCHI MASAO ET AL: "Nonreleasing basophils convert to releasing basophils by culturing with IL-3.", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 97, no. 6, 1996, pages 1279 - 1287, XP009007747, ISSN: 0091-6749 * |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8846043B2 (en) | 2001-11-07 | 2014-09-30 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer |
US7655234B2 (en) | 2001-11-07 | 2010-02-02 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer |
US7667018B2 (en) | 2001-11-07 | 2010-02-23 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer |
US7977062B2 (en) | 2001-11-07 | 2011-07-12 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer |
US8562989B2 (en) | 2001-11-07 | 2013-10-22 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer |
US8263355B2 (en) | 2005-03-21 | 2012-09-11 | Ronald Joseph Harbeck | Method and kit for detection of autoimmune chronic urticaria |
US7772011B2 (en) | 2005-03-21 | 2010-08-10 | Ronald Joseph Harbeck | Method and kit for detection of autoimmune chronic urticaria |
US8609432B2 (en) | 2005-03-21 | 2013-12-17 | Ronald Joseph Harbeck | Method and kit for detection of autoimmune chronic urticaria |
US8236310B2 (en) | 2005-03-31 | 2012-08-07 | Agensys, Inc. | Antibodies and related molecules that bind to 161P2F10B proteins |
EP1863848A2 (de) * | 2005-03-31 | 2007-12-12 | Agensys, Inc. | An 161p2f10b-proteine bindende antikörper und verwandte moleküle |
US8350009B2 (en) | 2005-03-31 | 2013-01-08 | Agensys, Inc. | Antibodies and related molecules that bind to 161P2F10B proteins |
EP2444099A1 (de) * | 2005-03-31 | 2012-04-25 | Agensys, Inc. | An 161P2F10B-Proteine bindende Antikörper und zugehörige Moleküle |
US7811565B2 (en) | 2005-03-31 | 2010-10-12 | Agensys, Inc. | Antibodies and related molecules that bind to 161P2F10B proteins |
EP1863848A4 (de) * | 2005-03-31 | 2009-09-23 | Agensys Inc | An 161p2f10b-proteine bindende antikörper und verwandte moleküle |
EP3300739A3 (de) * | 2005-03-31 | 2018-07-18 | Agensys, Inc. | An 161p2f10b-proteine bindende antikörper und zugehörige moleküle |
US8609092B2 (en) | 2010-02-08 | 2013-12-17 | Agensys, Inc. | Antibody drug conjugates (ADC) that bind to 161P2F10B proteins |
US9308278B2 (en) | 2010-02-08 | 2016-04-12 | Agensys, Inc. | Antibody drug conjugates (ADC) that bind to 161P2F10B proteins |
Also Published As
Publication number | Publication date |
---|---|
EP1454141B1 (de) | 2008-05-21 |
DE10160921A1 (de) | 2003-06-26 |
ATE396405T1 (de) | 2008-06-15 |
US20050003461A1 (en) | 2005-01-06 |
AU2002350717A1 (en) | 2003-06-17 |
EP1454141A1 (de) | 2004-09-08 |
DE10160921B4 (de) | 2005-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69405251T2 (de) | Methoden zur diagnose von allergie und prüfung anti-allergischer therapeutika | |
US20100209950A1 (en) | Granulocyte-based methods for detecting and monitoring immune system disorders | |
Farver et al. | Humoral measurement of type‐1 hypersensitivity reactions to a commercial Malassezia allergen | |
DE69731982T2 (de) | Verfahren zur messung der lymphozytenfunktion | |
DE60222121T2 (de) | Diagnose von metall-allergien durch zytokin-freigabe von t-zellen in vitro | |
EP1454141B1 (de) | Verfahren und verwendung eines antikörpers zum nachweis von allergien | |
DE102005006217B4 (de) | Diagnose von allergischen Erkrankungen und/oder atopischen Erkrankungen durch Nachweis von Autoantikörpern gegen CD28 in humanem Serum | |
EP2210097B1 (de) | Verfahren zur in vitro-diagnose und/oder in vitro-therapieverfolgung von infektionen | |
EP2010906B1 (de) | Verwendung des 4-1bb rezeptors zur identifizierung und/oder separation aktivierter regulatorischer th-zellen (treg) | |
EP0974050B1 (de) | Basophilen-degranulationstest | |
EP1179179B1 (de) | Verwendung eines antikörpers zur detektion von basophilen und/oder mastzellen | |
ROQUET et al. | No signs of activity markers in peripheral blood despite increased bronchial reactivity after repeated low‐dose allergen exposure | |
EP1044377B1 (de) | Verfahren zum nachweis von borna-disease-virus (bdv)- infektionen | |
Zakrzewska et al. | Expression of Fas ligand and CTLA4 in adenoids has a predictive value for allergic rhinitis development in children | |
DE10235310B4 (de) | Verfahren zur Bestimmung allergener Potenz von Produkten | |
DE69731983T2 (de) | Verwendung von molt4 cd69 expression zur bestimmung der anwesenheit und der aktivität von interferoninhibitoren | |
DE19925405C2 (de) | Verfahren zum Nachweis von spezifisch antigenreaktiven Lymphozyten sowie ein Nachweis-Kit zur Durchführung dieses Verfahrens | |
DE102009030845A1 (de) | Verfahren und Kit zur Diagnose oder Prognose einer Kontrastmittelallergie | |
DE102005048577A1 (de) | Verfahren zur Bestimmung der Menge von zellulär ausgeschiedenen detektierbaren Stoffen | |
EP1528395B1 (de) | Diagnostizierung von Erkrankungen und Prognostizierung von deren Verläufen über T-Helferzellen | |
DE19643427C1 (de) | Verfahren zur Bestimmung von Allergenen in der Luft | |
CH718721A1 (de) | In-vitro-Bestimmung von Coronavirus-Antigenen. | |
WO1997029370A1 (de) | Verfahren zur optimierung der auswahl eines basismedikamentes in einem individuellen therapieplan zur behandlung von störungen des immunsystems | |
DE102005002110A1 (de) | Regulatorische-T-Zellen enthaltend Proteine zur Therapie und Diagnose von Erkrankungen | |
DE102010024503A1 (de) | Verfahren und Testkit zum Nachweis antigenspezifischer T-Zellen zur Diagnostik von MAP-infizierten Tieren |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002785415 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10861892 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2002785415 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002785415 Country of ref document: EP |